Narrow Results

To identify a safe and effective Impaired Glucose Tolerance (IGT) intervention program using Traditional Chinese Medicine (TCM) supported by Standard Health Care Advice (SHCA) for the evidence-based TCM intervention in IGT and evidence-based prevention of type 2 diabetes. A total of 510 IGT patients were randomly assigned into either control or TCM intervention group (255 patients for each group). The control group received standard health care according to SHCA. The intervention group also received TCM intervention in addition to standard health care. The study was conducted over a three-year follow-up. At the end of three years follow-up, accumulative incidence and average annual incidence rate of diabetes in the control group was 43.86% and 14.62% respectively. Accumulative incidence and average annual incidence rate of diabetes in the TCM intervention group was 22.17% and 7.39% respectively. Compared with the control treatment, TCM intervention can reduce the relative risk of IGT patients progressing to type 2 diabetes by 49.45% and absolute risk by 21.69%. In the TCM intervention group, oral glucose tolerance test (OGTT), 2 h glucose, glycated hemoglobin, insulin resistance and body mass index were all significantly improved when compared to the control group. No significant side effect was observed during the follow-up in the TCM group. The SHCA-supported TCM intervention can reduce the conversion rate of IGT to diabetes and improve insulin resistance; therefore, it is a safe and effective IGT intervention strategy.

Traditional Chinese medicine (TCM) has a history of over 2000 years in treating infectious diseases, among which the clinical treatment of the common cold (colds) and influenza (flu) is the most widespread and well-established. It is difficult to tell the difference between a cold and the flu based on the symptoms alone. The flu vaccine protects against influenza, but there is no vaccine or specific medication to protect against the common cold. Due to the lack of a reliable scientific basis, TCM has not received sufficient attention in Western medicine. Therefore, we systematically evaluated the scientific evidence proving the efficacy of TCM intervention in treating colds for the first time by examining theoretical principles, clinical research, and pharmacological perspectives, as well as the mechanisms behind this efficacy. In TCM theory, there are four important external environmental factors that may cause a cold, which are called “cold, heat, dryness, and dampness”. The scientific basis for this theory has been described and will help researchers to understand and recognize its importance. The results of the systematic review of high-quality randomized controlled clinical trials (RCTs) have shown that TCM is effective and safe for the treatment of colds. Therefore, TCM might be used as a complementary or alternative approach to cold treatment and management. Some clinical trials have demonstrated that TCM may have potential therapeutic effects in preventing colds and treating their sequelae. However, more high-quality, large-scale randomized controlled trials should be conducted in the future for further verification. Pharmacological studies have shown that active ingredients extracted from TCM for treating colds have antiviral, anti-inflammatory, immune-regulating, and anti-oxidative properties. We expect that this review will guide the optimization and rationalization of TCM clinical practice and scientific research in the treatment of colds.

The use of sequential analysis in clinical rehabilitation research allows a spectrum of analyses in the comparison of two or more treatment protocols. Researchers in rehabilitation medicine are increasingly making use of sequential designs in their clinical investigations. This review serves to highlight the optimal use of the classical sequential designs presented by Armitage and Bross in the mid-twentieth century. A discussion of the limitations of this most basic sequential analysis is presented for the information of clinical researchers considering this study design. Examples of the use of classical and group sequential designs addressing both continuous and dichotomous outcomes are provided, and the advantages and disadvantages of classical and group sequential procedures as compared to fixed sample designs are illustrated with rehabilitation examples. As little literature has been published regarding the application of sequential analysis in clinical rehabilitation trials, clinical pharmacological, and medical trials in addition to medical statistical sources were used in this review.

This article deals about the Government Perspective on the Life Science in Taiwan.

AUSTRALIA — AIBN and Dow Launch Research Collaboration.

CHINA — US and China Ink Biofuels Cooperation Pact.

INDIA — Sanofi-Aventis Opens First Asian Pharmaceutical Development Center in India.

INDIA — India and France to Co-operate on Medical Research and Biotechnology.

INDONESIA — Bird Flu Resurfaces in Asia.

NEW ZEALAND — NZBio Launches Stem Cell Network.

NEW ZEALAND — Killer Hospital Superbug Infected 65 Patients.

SINGAPORE — MerLion Pharmaceuticals Wins Prestigious Pharmaceutical Industry Scrip Award.

SINGAPORE — ES Cell International Announces the Production of World's First Clinical-Grade Stem Cell Lines.

SINGAPORE — Association of Clinical Research Professionals Inaugurates Chapter in Singapore.

SOUTH KOREA — Disgraced South Korean Cloning Scientist Seeks Comeback.

SOUTH KOREA — Scientists Unlock Nanotube-Making Strain of Bacteria.

SOUTH KOREA — Samsung to Open Cancer Center.

GlaxoSmithKline and OncoMed Pharmaceuticals Form Strategic Alliance to Develop Cancer Stem Cell Antibody Therapeutics.

BioArctic Neuroscience and Eisai Enter Into Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease.

Japan Bioventures Today — Japan Animal Referral Medical Center.

Agilent Technologies Collaborates with BioNanomatrix to Develop Genetic Analysis System.

Eisai Opens Regional Clinical Research Center in Singapore.

GE Healthcare and Novavax to Develop and Market Pandemic Infuenza Solution.

Nanostart AG Marks Entry into Asia as Lead Investor in Singapore's Biomed Start-Up Curiox Biosystems.

QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products.

Binex and MaxCyte Collaborate on Cancer Immunotherapy Research.

ICRI Hosted International Conference on Trends in Clinical Research

AUSTRALIA – A New Skin Cancer Warning to the Over 60s

AUSTRALIA – Joint Venture to Establish up to 12 ATOS Wellness Centers in Australia

AUSTRALIA – New South Wales to Allow Cultivation of Genetically Modifed Canola

CHINA – Nanodrug for Pig's Foot-and-Mouth Disease

CHINA – Project for a Joint Biodiversity Lab in Yunnan Underway

CHINA – New Plants for Biofuel

INDIA – Texas Instruments — Indian Institute of Technology Pact

INDIA – Ranbaxy and Department of Biotechnology Tie-up for R&D

INDIA – Ayurvedic Association Agreement with American Herbal Association

INDIA – Indo-Dutch Ties Set to Further Advance Agribiotech Research

INDIA – Girl Undergoes Surgery in India to Gain Height

INDIA – Bioserve to Set up New Facility in Hyderabad with US$2 Million Investment

INDIA – Intas is Setting up India's First Plasma Fractionation Facility

JAPAN – AnGes Launches Naglazyme in Japan

KOREA – Health Institute Finds Needle-free Vaccination Method

KOREA – Scientists Find Gene Promoting Liver Cancer Growth

MALAYSIA – Dubai Group Invests in Southeast Asia's Largest Biodiesel Plant

MALAYSIA – Malaysia on Track to Become Biotech Hub

NEW ZEALAND – Blood Donors May Actually Become “Healthier”

SINGAPORE – Scientifc Pioneer Davor Solter Joins A*STAR to Nurture Next Generation of Researchers and Clinician-Scientists

SINGAPORE – Rockeby and National University of Singapore to Jointly Develop World's First Rapid Diagnostic Test Kit for Hand, Foot and Mouth Disease

SINGAPORE – Singaporean Research Team Develops First Cytotoxic Antibody against Undifferentiated Stem Cells

SINGAPORE – Singapore is Set to Promote Clinical Research in Public Hospitals

SINGAPORE – Singapore Heart Foundation to Raise Awareness of Heart Disease among Women

SINGAPORE – New Research Center Gets US$127 Million for Cancer Research

SINGAPORE – Wyeth to Expand State-of-the-Art Nutritional Manufacturing Facility in Singapore

TAIWAN – Taiwanese Patient Lives without Heart for 16 Days

TAIWAN – Joint Canada-Taiwan Biofuel Development Project Announced

TAIWAN – Researchers Find New Way to Probe Liver

THAILAND – Thai Scientist Cracks Rice Gene

Medicilon/MPI Pre-clinical Research-Shanghai Announces New President and Chief Operating Officer.

Singapore Honors Dutch Scientist for Low-cost Waste Water Treatment.

New CEO for AVA.

Spain's Minister for Health and Consumer Affairs Visits Singapore.

The Ribosome – a Restless Molecular Machine

An ICON in Clinical Research

Isilon: Scapes Up Big Data Storage

Biotron Hepatitis C Phase lla Trial Gives Positive Results.

WuXi PharmaTech Acquires China-Based Clinical Research Services Companies.

AztraZeneca Increases Investment in China with New $200 Million Manufacturing Facility.

Otsuka Commits $A25 Million to JV with LCT.

Norgine and Jubilant Announce Discovery Collaboration in Gastrointestinal Therapeutic Area.

SIRO Clinpharm and Peregrine Pharmaceuticals Highlight Successful Collaboration.

CMS Biologics Announces Agreement with Daiichi Sankyo Company to Develop and Manufacture Antibodies.

Chr. Hansen Partners with Amino Up to Develop Breakthrough Nutritional Formulations.

SK to Work with Chinese Company on Depression Meds.

Galderma & Singapore Immunology Network Work to Deepen Understanding of Acne.

BAYER HealthCare and Economic Development Board to foster translational and clinical research for diseases prevalent in Asia

Ludwig Cancer Research and University of Oxford launch Cancer Immunotherapy Spinout

OmniComm Systems® Announces Reseller Agreement with Tri-I Biotech Shanghai Inc. Market Leading Life Sciences Consultancy to Resell OmniComm’s TrialOne® eSource Solution

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement with Hepalink

Immunovaccine and PharmAthene Sign Exclusive Worldwide License Agreement to Develop and Commercialize an Anthrax Vaccine Formulated in DepoVax™

Commonwealth Financing Authority Announces New Alternative, Clean Energy Investment

ContraFect Corporation Announces Issuance of Key Patent Covering Novel Lysin Technology

M Pharmaceutical Inc. Rebrands Itself to Better Reflect Growing Family of Biomedical Technologies

Sustainable Apparel Coalition Recognizes SCS Global Services as Approved Verifier for New Pilot Program

StemCell United Announces Plans for PO and Listing on ASX

Roche Diagnostics Strengthens Footprint in Asia Pacific

NRGene delivers first-ever food potato genomes.

CMC Biologics announces development and manufacturing agreement with Harpoon Therapeutics.

Typhoid vaccine prequalified.

Clearbridge BioMedics’ ClearCell FX1 system achieves U.S. FDA listing.

Singapore eDevelopment names Dr Roscoe Moore as senior scientific adviser to its biomedical arm.

Varian Halcyon treatment system receives Taiwan FDA approval.

Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration.

AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics.

Illumina Launches iSeq 100 Sequencing System.

iGENE Laboratory granted licence by MOH to perform non-invasive prenatal test in Singapore.

Clarivate Analytics appoints new president for life sciences division.

Watsons partners with ChromaDex, to launch TRU NIAGEN in Singapore.

Colorcon, Inc. transforms sugar coating process with new Opadry System.

GSK Consumer Healthcare appoints Filippo Lanzi as head for Asia Pacific.

Chugai obtains approval for TECENTRIQ for treatment of unresectable, advanced or recurrent non-small cell lung cancer.

Historic deal signed between Panacea Biotec and Serum Institute of India.

me+ to partner Singapore Clinical Research Institute on new innovative healthcare solutions.

Traditional Chinese medicine (TCM) plays an active role in the prevention and control of COVID-19 epidemic. Currently, there are many TCM intervention programs for the COVID-19 infections, and the clinical effect is better. However, there are some problems in the design of actual clinical programs. This paper analyzes the advantages and disadvantages of various TCM interventions for the COVID-19 infection from the perspective of scientific and clinical research. We can scientifically use the TCM theory to guide and design clinical research, and come up with real data and treatment, to provide new models and explorations for the research of the modernization of Chinese medicine.

This chapter covers the statistical techniques using linear regression for quantitative outcomes, logistic regression for qualitative outcomes and Cox regression for time-to-event outcomes. Examples of result interpretation and presentation by means of tables for univariate and multivariate analyses were shown.

Objective: To evaluate the therapeutic effect of Bufeiyishen Granule on chronic obstructive pulmonary disease (COPD) through clinical and experimental studies.

Methods: In the clinical study, 62 stable COPD patients were divided into treatment group and control group, treated for six months, and observed for changes of lung function and number of acute exacerbation. In the experimental study, 105 rats were randomly divided into seven groups (control group, stable model group, acute exacerbation model group, high-dose group, low-dose group, Flumucil group, and Yupingfeng group), and measured for routine blood test, artery blood gas, bronchoalveolar lavage fluid (BALF), lung function, pathological changes and matrix metalloproteinases (MMPs) at measurement points.

Results: In the clinical study, forced expiratory volume in one second, maximum mid-expiratory flow rate, peak expiratory volume and FEV1% were increased significantly (p < 0.05, p < 0.01), and the number of acute exacerbations was remarkably decreased (p < 0.01) in treatment group, but no obvious changes were found in control group. The experimental study showed higher leukocyte and neutrophil counts in the peripheral blood, bronchial BALF in the acute exacerbation model group, together with elevated levels of blood gas PaCO₂, MMP-9 and MMP-2, and worse lung function and blood gas PaO₂ as compared to the control and stable model groups; the low-dose group could improve the above changes.

Conclusion: Bufeiyishen Granule could improve the lung function in stable COPD patients and decrease the number of acute exacerbation. Animal models of stable COPD and acute exacerbation state were successfully created. Bufeiyishen Granule could also improve the changes of MMPs in COPD.